Know Cancer

or
forgot password

Maintenance of Chemotherapy Following Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Rectal Neoplasms

Thank you

Trial Information

Maintenance of Chemotherapy Following Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer


Research has shown that low rectal cancer treated with neoadjuvant chemoradiation (54Gy
concurrent with 3 cycles of 5-FU/Leucovorin) followed by 3 additional cycles of
5FU/Leucovorin, followed by close follow-up (every 4-6 weeks for one year)has had good
success in achieving complete clinical response, avoiding surgical intervention. If at
follow-up remaining disease is found or if there is recurrent disease, surgery can be
performed.


Inclusion Criteria:



- over 18 years old

- tumor potentially resectable en bloc; tumors tethered or fixed to a structure that
can be removed

- clinical/radiological stages T2,T3,or T4, N0-1

- ANC >1500, PLT>100,000

- AST and alkaline phosphatase < 2.5 X ULN

- bilirubin < 1.5 X ULN

- CrCl > 50 ml/min using Cockcroft-Gault formula

- KPS >60

- ECOG Performance Scale 0-2

- No malignancies within previous 5 years other than non-melanoma skin cancer, in-situ
cervical cancer, in-situ ductal breast cancer

- no evidence of metastatic disease

Exclusion Criteria:

- initial tumor fixation to pelvic bone or side wide; technically unresectable disease

- any evidence of distant metastasis

- perforation

- obstruction

- hereditary non-polyposis colorectal cancer

- synchronous primary colon carcinomas except T1 lesions

- known dihydropyrimidine dehydrogenase deficiency

- prior radiation therapy to the pelvis

- prior chemotherapy for malignancies

- known existing uncontrolled coagulopathy

- pregnancy or lactation

- women of childbearing potential not using reliable and appropriate contraceptive
method

- serious, uncontrolled concurrent infection(s)

- participation in any investigational drug study within 4 weeks preceding the start of
study treatment

- clinically significant heart disease

- other serious uncontrolled medical conditions that might compromise study
participation (in the investigator's opinion)

- major surgery within 4 weeks prior to the study treatment

- lack of physical integrity of the upper GI tract or malabsorption syndrome

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To assess the complete clinical response rate following neoadjuvant chemoradiation in patients with distal rectal cancer.

Outcome Description:

Primary endpoints are the proportion of subjects with complete clinical response to chemoradiation therapy at no sooner than 9 weeks from treatment completion, and maintenance of continuous freedom from local failure for one year.

Outcome Time Frame:

One year from the time of chemoradiation

Safety Issue:

No

Principal Investigator

John Marks, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Main Line Health

Authority:

United States: Food and Drug Administration

Study ID:

R12-3092L

NCT ID:

NCT01613469

Start Date:

August 2011

Completion Date:

August 2014

Related Keywords:

  • Rectal Neoplasms
  • fluorouracil
  • leucovorin
  • radiotherapy
  • neoadjuvant therapy
  • Neoplasms
  • Rectal Neoplasms

Name

Location

Lankenau Medical CenterWynnewood, Pennsylvania  19096